92 related articles for article (PubMed ID: 3818387)
1. Changes of the blood lymphocyte population following 131I treatment for nodular goiter.
Blomgren H; Petrini B; Wasserman J; Schnell PO; Lundell G
Int J Radiat Oncol Biol Phys; 1987 Feb; 13(2):209-15. PubMed ID: 3818387
[TBL] [Abstract][Full Text] [Related]
2. Changes of the blood lymphocyte subpopulations and their functions following 131I treatment for nodular goitre and 32P treatment for polycythemia vera.
Wasserman J; Blomgren H; Petrini B; Svedmyr E; Schnell PO; Lundell G; Von Stedingk LV
Int J Radiat Biol Relat Stud Phys Chem Med; 1988 Jan; 53(1):159-67. PubMed ID: 3257474
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine 131I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine 131I activity to be administered in patients with low uptake.
Ceccarelli C; Antonangeli L; Brozzi F; Bianchi F; Tonacchera M; Santini P; Mazzeo S; Bencivelli W; Pinchera A; Vitti P
Thyroid; 2011 Jul; 21(7):759-64. PubMed ID: 21568727
[TBL] [Abstract][Full Text] [Related]
4. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.
Nygaard B; Faber J; Veje A; Hegedüs L; Hansen JM
Thyroid; 1999 May; 9(5):477-81. PubMed ID: 10365679
[TBL] [Abstract][Full Text] [Related]
5. Blood lymphocyte population following 131I treatment for hyperthyroidism.
Blomgren H; Wasserman J; Petrini B; von Stedingk LV
Acta Endocrinol (Copenh); 1991 Feb; 124(2):152-8. PubMed ID: 1825898
[TBL] [Abstract][Full Text] [Related]
6. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter.
Nygaard B; Jarløv AE; Kristensen LO; Faber J
Horm Metab Res; 2000 Jul; 32(7):283-7. PubMed ID: 10965935
[TBL] [Abstract][Full Text] [Related]
8. 131I therapy of toxic and non-toxic goiters.
Beckers C
Q J Nucl Med; 1999 Dec; 43(4):291-6. PubMed ID: 10731779
[TBL] [Abstract][Full Text] [Related]
9. Standard dose 131I therapy for toxic multinodular goiter in an endemic goiter region.
Gonçalves E; Castro JA; Gross JL
Braz J Med Biol Res; 1986; 19(6):723-9. PubMed ID: 3651625
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy.
Fast S; Hegedüs L; Grupe P; Nielsen VE; Bluhme C; Bastholt L; Bonnema SJ
J Clin Endocrinol Metab; 2010 Aug; 95(8):3719-25. PubMed ID: 20519346
[TBL] [Abstract][Full Text] [Related]
11. The effects of a custom-made lead collar on dose rates of patients treated with 131I.
Stapel AG; van der Zant FM; Gommans GM; Boer RO; Reigman HI
Health Phys; 2009 May; 96(5 Suppl 2):S64-8. PubMed ID: 19359844
[TBL] [Abstract][Full Text] [Related]
12. [Development of Basedow disease after radioiodine therapy for nodular goiter].
Cseke B; Balázs C
Orv Hetil; 2003 Nov; 144(47):2327-9. PubMed ID: 14725052
[TBL] [Abstract][Full Text] [Related]
13. Effect of 32P treatment for polycythaemia vera on blood lymphocyte subpopulations and their functions.
Petrini B; Blomgren H; Wasserman J; Svedmyr E; Stedingk LV; Schnell PO
Eur J Haematol; 1987 Sep; 39(3):221-7. PubMed ID: 3678473
[TBL] [Abstract][Full Text] [Related]
14. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter.
Huysmans DA; Nieuwlaat WA; Erdtsieck RJ; Schellekens AP; Bus JW; Bravenboer B; Hermus AR
J Clin Endocrinol Metab; 2000 Oct; 85(10):3592-6. PubMed ID: 11061507
[TBL] [Abstract][Full Text] [Related]
15. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.
Antonelli A; Rotondi M; Fallahi P; Grosso M; Boni G; Ferrari SM; Romagnani P; Serio M; Mariani G; Ferrannini E
J Clin Endocrinol Metab; 2007 Apr; 92(4):1485-90. PubMed ID: 17244787
[TBL] [Abstract][Full Text] [Related]
16. Relapses of hyperthyroidism in patients treated with radioiodine for nodular toxic goiter: relation to thyroid autoimmunity.
Custro N; Ganci A; Scafidi V
J Endocrinol Invest; 2003 Feb; 26(2):106-10. PubMed ID: 12739735
[TBL] [Abstract][Full Text] [Related]
17. [Autoimmunization and multinodular large toxic goiter therapy using repeated doses of 131I].
Pisarek M; Baczyk M; Gryczyńska M; Pietz L; Ziemnicka K; Sowiński J
Pol Arch Med Wewn; 2006 Jun; 115(6):545-50. PubMed ID: 17263226
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial.
Nielsen VE; Bonnema SJ; Boel-Jørgensen H; Veje A; Hegedüs L
J Clin Endocrinol Metab; 2005 Jan; 90(1):79-83. PubMed ID: 15494456
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine for nontoxic multinodular goiter.
Huysmans D; Hermus A; Edelbroek M; Barentsz J; Corstens F; Kloppenborg P
Thyroid; 1997 Apr; 7(2):235-9. PubMed ID: 9133693
[TBL] [Abstract][Full Text] [Related]
20. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
